Neuropathic pain drugs based on the endogenous opioid peptide Endomorphin 1.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/569855

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

We have developed a new pain drug based on the natural pain killing opioid peptide, Endomorhin 1. The new drug exhibits activity similar to morphine and gabapentin against neuropathic pain in animals but seems to act through a different mechanism. We will complete our preclinical investigation of this compound by assessing its side effect profile and tolerence inducing properties in animals. We will also continue our development of an orally active analogue of this important peptide.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2010

Funding Scheme: NHMRC Development Grants

Funding Amount: $209,470.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical biochemistry - amino acids and metabolites

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Diabetic neuropathy | Nerve injury | Neuropathic pain | Neuropeptides | Opioid receptors | Preclinical drug development

Related Links